{"id":23,"date":"2024-02-28T09:29:40","date_gmt":"2024-02-28T09:29:40","guid":{"rendered":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/?page_id=23"},"modified":"2024-06-26T15:46:36","modified_gmt":"2024-06-26T15:46:36","slug":"news","status":"publish","type":"page","link":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/news\/","title":{"rendered":"News"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Banner Section&#8221; module_class=&#8221;orangeShape innerBanner&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-content\/uploads\/2024\/06\/205_KSQ_2024.02.01_Genevieve-de-Manio-Photography-scaled-e1719331769716.jpg&#8221; background_position=&#8221;top_center&#8221; background_enable_video_mp4=&#8221;off&#8221; height=&#8221;500px&#8221; overflow-x=&#8221;hidden&#8221; overflow-y=&#8221;hidden&#8221; custom_padding=&#8221;199px||199px||true|false&#8221; bottom_divider_height=&#8221;500px&#8221; background_last_edited=&#8221;on|phone&#8221; background_position_phone=&#8221;top_right&#8221; background_horizontal_offset_phone=&#8221;6%&#8221; da_popup_slug=&#8221;platform&#8221; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; width_tablet=&#8221;100%&#8221; width_phone=&#8221;100%&#8221; width_last_edited=&#8221;on|desktop&#8221; max_width=&#8221;100%&#8221; overflow-x=&#8221;hidden&#8221; overflow-y=&#8221;hidden&#8221; custom_margin=&#8221;|60px||60px|false|true&#8221; custom_margin_tablet=&#8221;|20px||20px|false|true&#8221; custom_margin_phone=&#8221;|20px||20px|false|true&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding_tablet=&#8221;0px||0px||true|false&#8221; custom_padding_phone=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;Vertical Line&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; positioning=&#8221;absolute&#8221; width=&#8221;100%&#8221; height=&#8221;100%&#8221; animation_style=&#8221;slide&#8221; animation_direction=&#8221;top&#8221; border_width_left=&#8221;6px&#8221; border_color_left=&#8221;#FFFFFF&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_text][et_pb_cta title=&#8221;NEWS&#8221; admin_label=&#8221;Call To Action&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;Nunito Sans|700||on|||||&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_font_size=&#8221;20px&#8221; header_letter_spacing=&#8221;1px&#8221; header_line_height=&#8221;20px&#8221; body_font=&#8221;Nunito Sans|300||on|||||&#8221; body_text_color=&#8221;#FFFFFF&#8221; body_font_size=&#8221;40px&#8221; body_letter_spacing=&#8221;0.5px&#8221; body_line_height=&#8221;44px&#8221; use_background_color=&#8221;off&#8221; text_orientation=&#8221;left&#8221; max_width=&#8221;500px&#8221; custom_padding=&#8221;10px||10px|25px|true|false&#8221; animation_style=&#8221;slide&#8221; animation_direction=&#8221;left&#8221; animation_delay=&#8221;900ms&#8221; header_font_size_tablet=&#8221;20px&#8221; header_font_size_phone=&#8221;20px&#8221; header_font_size_last_edited=&#8221;on|phone&#8221; body_font_size_tablet=&#8221;30px&#8221; body_font_size_phone=&#8221;30px&#8221; body_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>NEW FRONTIERS IN CANCER TREATMENT<\/p>\n<p>[\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; custom_padding_last_edited=&#8221;on|phone&#8221; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; custom_padding_tablet=&#8221;50px||50px||true|false&#8221; custom_padding_phone=&#8221;50px||50px||true|false&#8221; da_disable_devices=&#8221;off|off|off&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; width_tablet=&#8221;100%&#8221; width_phone=&#8221;100%&#8221; width_last_edited=&#8221;on|desktop&#8221; custom_padding_tablet=&#8221;0px|20px|0px|20px|true|true&#8221; custom_padding_phone=&#8221;0px|20px|0px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Press Releases&#8221; admin_label=&#8221;Press Releases&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;|800||on|||||&#8221; title_text_align=&#8221;left&#8221; title_text_color=&#8221;#4db2c5&#8243; title_font_size=&#8221;24px&#8221; title_line_height=&#8221;34px&#8221; custom_margin=&#8221;0px||20px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]\n    <div class=\"press-releases-container\">\n        <form id=\"press-releases-filter\" method=\"get\">\n            <label for=\"release-year\">Year<\/label>\n            <select name=\"release-year\" id=\"release-year\">\n                <option value=\"\">All Years<\/option>\n                <option value=\"2024\" >2024<\/option><option value=\"2023\" >2023<\/option>            <\/select>\n            <button type=\"submit\">Filter<\/button>\n        <\/form>\n\n        <div id=\"press-releases-list\">\n                                <div class=\"press-release-item\">\n                        <div class=\"press-release-date\">06\/12\/2024<\/div>\n                        <div class=\"press-release-title\"><h2><a href=\"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/press-releases\/ksq-therapeutics-announces-first-patient-dosed-in-clinical-development-program-for-ksq-001ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy\/\">KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR\/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL<sup>\u00ae<\/sup>) Therapy<\/a><\/h2><\/div>\n                        <div class=\"press-release-excerpt\"><p>Lexington, Mass., June 12, 2024\u00a0\u2014\u00a0KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1\/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of TIL in which the SOCS1 gene is inactivated by CRISPR\/Cas9 gene&#8230;<\/p>\n<\/div>\n                    <\/div>\n                                    <div class=\"press-release-item\">\n                        <div class=\"press-release-date\">11\/29\/2023<\/div>\n                        <div class=\"press-release-title\"><h2><a href=\"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/press-releases\/ksq-therapeutics-announces-fda-clearance-of-ind-application-for-ksq-001ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy\/\">KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR\/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL<sup>\u00ae<\/sup>) Therapy<\/a><\/h2><\/div>\n                        <div class=\"press-release-excerpt\"><p>Phase 1\/2 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KSQ-001EX in melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer\u00a0 Lexington, Mass., November 29, 2023\u00a0\u2014\u00a0KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University&#8230;<\/p>\n<\/div>\n                    <\/div>\n                                    <div class=\"press-release-item\">\n                        <div class=\"press-release-date\">09\/06\/2023<\/div>\n                        <div class=\"press-release-title\"><h2><a href=\"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/press-releases\/ksq-therapeutics-and-ctmc-announce-strategic-collaboration-to-accelerate-the-development-of-novel-engineered-tumor-infiltrating-lymphocyte-etil-therapies-for-the-treatment-of-solid-tumors\/\">KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL<sup>\u00ae<\/sup>) Therapies for the Treatment of Solid Tumors<\/a><\/h2><\/div>\n                        <div class=\"press-release-excerpt\"><p>Collaboration will provide full process development and manufacturing support for KSQ\u2019s lead eTIL programs Lexington, Mass., September 6, 2023\u00a0\u2014\u00a0KSQ Therapeutics, Inc. (\u201cKSQ\u201d), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics\u00ae\u00a0discovery platform, and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced today&#8230;<\/p>\n<\/div>\n                    <\/div>\n                                    <div class=\"press-release-item\">\n                        <div class=\"press-release-date\">07\/23\/2023<\/div>\n                        <div class=\"press-release-title\"><h2><a href=\"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/press-releases\/ksq-therapeutics-enters-worldwide-license-agreement-with-roche-for-ksq-4279-a-clinical-stage-usp1-inhibitor-for-cancer\/\">KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer<\/a><\/h2><\/div>\n                        <div class=\"press-release-excerpt\"><p>Lexington, Mass., July 13, 2023 \u2014\u00a0KSQ Therapeutics, Inc. (\u201cKSQ\u201d), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics\u00ae\u00a0discovery platform, announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279. KSQ-4279 is a first-in-class, potent, and selective small&#8230;<\/p>\n<\/div>\n                    <\/div>\n                                    <div class=\"press-release-item\">\n                        <div class=\"press-release-date\">05\/17\/2023<\/div>\n                        <div class=\"press-release-title\"><h2><a href=\"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/press-releases\/ksq-therapeutics-and-takeda-expand-strategic-immuno-oncology-collaboration-to-identify-and-validate-novel-tumor-targets\/\">KSQ Therapeutics and Takeda Expand Strategic Immuno-Oncology Collaboration to Identify and Validate Novel Tumor Targets<\/a><\/h2><\/div>\n                        <div class=\"press-release-excerpt\"><p>Expanded collaboration focused on novel target discovery and validation to inform the development of targeted therapies that address resistance mechanisms in patients with cancer Agreement expands the companies\u2019 successful ongoing collaboration focused on discovering natural killer (NK) and T-cell targets Lexington, Mass., May 17, 2023\u00a0KSQ Therapeutics, (\u201cKSQ\u201d), a clinical-stage biotechnology&#8230;<\/p>\n<\/div>\n                    <\/div>\n                        <\/div>\n\n            <\/div>\n    [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Banner Section&#8221; module_class=&#8221;orangeShape innerBanner&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-content\/uploads\/2024\/06\/205_KSQ_2024.02.01_Genevieve-de-Manio-Photography-scaled-e1719331769716.jpg&#8221; background_position=&#8221;top_center&#8221; background_enable_video_mp4=&#8221;off&#8221; height=&#8221;500px&#8221; overflow-x=&#8221;hidden&#8221; overflow-y=&#8221;hidden&#8221; custom_padding=&#8221;199px||199px||true|false&#8221; bottom_divider_height=&#8221;500px&#8221; background_last_edited=&#8221;on|phone&#8221; background_position_phone=&#8221;top_right&#8221; background_horizontal_offset_phone=&#8221;6%&#8221; da_popup_slug=&#8221;platform&#8221; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; width_tablet=&#8221;100%&#8221; width_phone=&#8221;100%&#8221; width_last_edited=&#8221;on|desktop&#8221; max_width=&#8221;100%&#8221; overflow-x=&#8221;hidden&#8221; overflow-y=&#8221;hidden&#8221; custom_margin=&#8221;|60px||60px|false|true&#8221; custom_margin_tablet=&#8221;|20px||20px|false|true&#8221; custom_margin_phone=&#8221;|20px||20px|false|true&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding_tablet=&#8221;0px||0px||true|false&#8221; custom_padding_phone=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243;&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"<!-- wp:divi\/placeholder \/-->","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"class_list":["post-23","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/pages\/23","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/comments?post=23"}],"version-history":[{"count":16,"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/pages\/23\/revisions"}],"predecessor-version":[{"id":3142,"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/pages\/23\/revisions\/3142"}],"wp:attachment":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/media?parent=23"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}